We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+59.01%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$720M
AUM Growth
-$21.6M
Cap. Flow
-$169M
Cap. Flow %
-23.52%
Top 10 Hldgs %
49.7%
Holding
103
New
21
Increased
18
Reduced
27
Closed
35

Top Buys

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$23.5M
2
IMNM icon
Immunome
IMNM
+$19.8M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.1M
4
COGT icon
Cogent Biosciences
COGT
+$12.1M
5
PFE icon
Pfizer
PFE
+$10.6M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$36.8M
2
AKRO
Akero Therapeutics
AKRO
+$30.6M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$24.8M
4
INSM icon
Insmed
INSM
+$24.7M
5
CDTX
Cidara Therapeutics
CDTX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TELA icon
51
TELA Bio
TELA
$31.8M
$3.12M 0.43%
2,647,512
-135,411
-5% -$171K
QURE icon
52
uniQure
QURE
$2.93B
$3.02M 0.42%
126,047
-328,953
-72% -$12.7M
TARS icon
53
Tarsus Pharmaceuticals
TARS
$2.6B
$2.96M 0.41%
+36,124
New +$2.7M
KYMR icon
54
Kymera Therapeutics
KYMR
$8.8B
$2.69M 0.37%
+34,589
New +$2.34M
RARE icon
55
CALL
Ultragenyx Pharmaceutical
RARE
$2.56B
$2.53M 0.35%
110,000
-418,200
-79% -$13.8M
NXTC icon
56
NextCure
NXTC
$20.5M
$2.5M 0.35%
+176,057
New +$1.82M
ELUT icon
57
Elutia
ELUT
$40M
$1.91M 0.26%
2,751,314
-99,673
-3% -$75.7K
SION
58
Sionna Therapeutics
SION
$2.11B
$1.71M 0.24%
41,460
-67,341
-62% -$2.55M
CTMX icon
59
CytomX Therapeutics
CTMX
$714M
$1.64M 0.23%
+385,974
New +$1.47M
XFOR icon
60
X4 Pharmaceuticals
XFOR
$377M
$1.43M 0.2%
+357,387
New +$1.3M
EWTX icon
61
Edgewise Therapeutics
EWTX
$4.42B
$1.04M 0.14%
+42,052
New +$844K
RADX
62
Radiopharm Theranostics
RADX
$25.2M
$978K 0.14%
187,406
– –
FDMT icon
63
4D Molecular Therapeutics
FDMT
$526M
$750K 0.1%
+100,000
New +$1.01M
ADGM
64
Adagio Medical Holdings
ADGM
$8.32M
$536K 0.07%
+515,384
New +$611K
RAPP
65
Rapport Therapeutics
RAPP
$2.05B
$293K 0.04%
9,659
-194,287
-95% -$5.38M
PALI icon
66
Palisade Bio
PALI
$341M
$240K 0.03%
+102,108
New +$196K
IBIO icon
67
iBio
IBIO
$69.1M
$205K 0.03%
+106,000
New +$145K
RCKTW icon
68
Rocket Pharmaceuticals Warrant
RCKTW
$342K
$2.55K ﹤0.01%
104,828
– –
AKRO
69
DELISTED
Akero Therapeutics
AKRO
– –
-643,636
Closed -$30.6M
ALKS icon
70
Alkermes
ALKS
$8.39B
– –
-180,513
Closed -$5.42M
ARCT icon
71
Arcturus Therapeutics
ARCT
$168M
– –
-3,445
Closed -$63.5K
ARCT icon
72
PUT
Arcturus Therapeutics
ARCT
$168M
– –
-42,000
Closed -$774K
BDSX icon
73
Biodesix
BDSX
$221M
– –
-49,607
Closed -$375K
CAMP icon
74
CAMP4 Therapeutics
CAMP
$180M
– –
-653,594
Closed -$1.96M
CAPR icon
75
PUT
Capricor Therapeutics
CAPR
$243M
– –
-144,700
Closed -$1.04M
1 2
3
4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Silverarc Capital Management held 103 positions worth $720M, down 2.9% from $742M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management withdrew a net $169M in Q4 2025, closing 35 positions and reducing 27 holdings. Its most notable exit was Avidity Biosciences, an estimated $36.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in Immunome worth $24.2M.

  • Silverarc Capital Management's largest Q4 2025 buy was Immunome: 1,126,210 shares worth $24.2M.
  • Silverarc Capital Management added most to Celcuity in Q4 2025, an estimated $23.5M increase.
  • Silverarc Capital Management's biggest Q4 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $24.8M.
  • Silverarc Capital Management fully exited Avidity Biosciences in Q4 2025, selling an estimated $36.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $720M portfolio in Q4 2025.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q4 2025.
  • Silverarc Capital Management's portfolio value fell 2.9% quarter-over-quarter to $720M.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.